Any general news stories or articles in the media we believe are of interest to you
You are here
News story
UCLH study: web-based video consultations
A study is being sponsored by UCL School of Pharmacy in London to look into the acceptability of web-based video consultations for patients who are receiving treatment for CML at University College London Hospital UCLH.
To help with this, we are looking for people with CML to take part in a focus group to help the study team understand if the opinions of UCLH patients are similar to those of the wider CML patient population.
- Read more about UCLH study: web-based video consultations
- Log in or register to post comments
- Email this page
BCR-ABL1 levels increase in peripheral blood but not in granulocytes after physical exercise
In chronic myeloid leukemia (CML) treatment response is determined by measurements of BCR-AB1L transcripts in peripheral blood by quantitative real-time PCR (qRT-PCR) and a 2–5 fold increase is considered a warning sign. The BCR-ABL1 gene is mainly expressed in myeloid cells whereas quantification of BCR-ABL1 is performed on the nucleated cell fraction of peripheral blood. Hence, leukocyte composition of the nucleated cell fraction may affect the result of BCR-ABL1 quantification.
Pepsi or Coke? Influence of acid on dasatinib absorption
Dasatinib's bioavailability is highly dependent on gastric pH. When proton-pump inhibitors (PPIs) are co-administered with dasatinib, absorption is significantly reduced. Cola intake at the time of drug administration has been demonstrated to lead to relevant increases in the bioavailability for other acid labile drugs during PPI treatment. This manuscript reviews the relevant literature supporting a strategy of temporarily lowering the gastric pH with a carbonated beverage at the time of drug administration.
UK CML Patient Conference 2018 (22 Sept): Video Recordings Now Available
The UK CML Patient Conference: '22/09 World CML Day' Saturday 22nd September 2018.
The event has now taken place, and video recordings of the main presentations are available on this page.
Click on the link in each agenda item to view the corresponding presentation.
AGENDA
Chronic Myeloid Leukaemia Patient Day. Saturday 22nd September 2018 'World CML Day'.
Organised by Professor Mhairi Copland on behalf of the NCRI CML Sub-Group.
In Memoriam: Tessa Holyoake
Tessa Holyoake was a giant in the world of CML and her loss to the research community, patients and her fellow specialist clinicians is and will continue to be keenly felt.
- Read more about In Memoriam: Tessa Holyoake
- Log in or register to post comments
- Email this page
Striving to vanquish leukaemia: Combination of two compounds shows promise in the lab
Cancer cells are escape artists by nature. They can dodge drugs designed to cripple them due to one of their defining characteristics: their genetic makeup changes rapidly. Cancer cells are constantly evolving, and, given the right mutation, they’re able to evade treatment.
PegIFN Improves Responses to Dasatinib in Newly Diagnosed CML Patients
News | May 03, 2016
The addition of pegylated interferon-ɑ2b (PegIFN) to the tyrosine kinase inhibitor (TKI) dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukaemia (CML) patients.
Dasatinib Commonly Induces Lymphocytosis in CML Patients
News | March 29, 2016 | Chronic Myeloid Leukaemia, Cancer Complications, Haematologic Malignancies, Leukaemia & Lymphoma
By Dave Levitan
Patients with chronic myeloid leukemia (CML) who are treated with the tyrosine kinase inhibitor (TKI) dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib, according to a new study.
International CML Foundation- November 2015 Newsletter
The International CML Foundation (iCMLf) is a Foundation established by a group of leading hematologists with a strong interest in CML. The mission of the iCMLf is to improve the outcomes for patients with CML globally. The Foundation is registered as a charitable organisation in England and Wales but its charter is global. Its aims are to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML, especially in emerging economic regions.